| Literature DB >> 28912840 |
Xiao-Hua Yang1,2, Jian-Bin Su1,3, Xiu-Lin Zhang4, Li-Hua Zhao3, Feng Xu3, Xue-Qin Wang3, Xing-Bo Cheng1.
Abstract
BACKGROUND: Reduced insulin sensitivity not only contributes to the pathogenesis of type 2 diabetes but is also linked to multiple metabolic risk factors and cardiovascular diseases (CVD). A prolonged heart rate-corrected QT interval (QTc interval) is related to ventricular arrhythmias and CVD mortality and exhibits a high prevalence among type 2 diabetes patients. The aim of the study was to investigate the relationship between insulin sensitivity and the QTc interval in patients with type 2 diabetes.Entities:
Keywords: Insulin sensitivity; QTc interval; Type 2 diabetes
Year: 2017 PMID: 28912840 PMCID: PMC5594484 DOI: 10.1186/s13098-017-0268-3
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 3.320
Clinical characteristics of the participants according to ISIMatsuda quartiles
| Variables | Total | Q1 | Q2 | Q3 | Q4 |
|
|---|---|---|---|---|---|---|
| ISIMatsuda | 99.4 (65.9–151.8) | 48.2 (36.9–57.9) | 82.0 (73.6–89.8) | 120.7 (109.5–135.4) | 214.8 (175.0–289.8) | <0.001 |
| log ISIMatsuda | 4.61 ± 0.67 | 3.78 ± 0.36 | 4.40 ± 0.12 | 4.80 ± 0.16 | 5.46 ± 0.37 | <0.001 |
|
| 2927 | 733 | 727 | 730 | 737 | – |
| Age (years) | 56 ± 14 | 57 ± 14 | 56 ± 14 | 56 ± 13 | 55 ± 13 | 0.280 |
| Female, n (%) | 1394 (47.6) | 428 (58.4) | 368 (50.6) | 298 (40.8) | 300 (40.7) | <0.001 |
| BMI (kg/m2) | 25.0 ± 3.9 | 26.3 ± 4.1 | 25.5 ± 3.9 | 24.5 ± 3.6 | 23.6 ± 3.3 | <0.001 |
| SBP (mmHg) | 135 ± 17 | 137 ± 17 | 136 ± 18 | 134 ± 17 | 132 ± 18 | <0.001 |
| DBP (mmHg) | 80 ± 11 | 80 ± 10 | 80 ± 11 | 80 ± 10 | 79 ± 11 | 0.073 |
| Diabetic duration (years) | 3.0 (0.3–9.0) | 4.0 (0.3–10.0) | 3.0 (0.3–10.0) | 3.0 (0.3–8.0) | 3.0 (0.3–9.0) | 0.209 |
| Antidiabetic treatment | ||||||
| Lifestyle intervention alone, n (%) | 313 (10.7) | 69 (9.4) | 71 (9.8) | 79 (10.8) | 94 (12.8) | 0.067 |
| Insulin treatments, n (%) | 871 (29.8) | 259 (35.3) | 217 (29.8) | 198 (27.1) | 197 (26.7) | 0.031 |
| Insulin-secretagogues, n (%) | 1168 (39.9) | 255 (34.8) | 304 (41.8) | 328 (44.9) | 281 (38.1) | 0.106 |
| Insulin-sensitisers, n (%) | 1873 (64.0) | 455 (62.1) | 470 (64.6) | 491 (67.3) | 457 (62.0) | 0.765 |
| Hypertension, n (%) | 1089 (37.2) | 338 (46.1) | 306 (42.1) | 252 (34.5) | 193 (26.2) | <0.001 |
| Statins medication, n (%) | 1079 (36.9) | 303 (41.3) | 296 (40.7) | 264 (36.2) | 216 (29.3) | <0.001 |
| Smoking, n (%) | 892 (30.5) | 231 (31.5) | 232 (31.9) | 215 (29.5) | 215 (29.0) | 0.193 |
| Drinking, n (%) | 476 (16.3) | 159 (21.7) | 131 (18.0) | 119 (16.3) | 67 (9.1) | <0.001 |
| CHD, n (%) | 262 (9.0) | 82 (11.2) | 74 (10.2) | 49 (6.7) | 57 (7.7) | 0.008 |
| TG (mmol/L) | 1.61 (1.02–2.59) | 2.06 (1.33–3.20) | 1.76 (1.15–2.74) | 1.56 (1.00–2.47) | 1.15 (0.77–1.86) | <0.001 |
| TC (mmol/L) | 4.73 ± 1.25 | 4.82 ± 1.43 | 4.81 ± 1.21 | 4.75 ± 1.19 | 4.53 ± 1.14 | <0.001 |
| HDLC (mmol/L) | 1.07 ± 0.29 | 1.03 ± 0.26 | 1.06 ± 0.26 | 1.07 ± 0.30 | 1.13 ± 0.31 | <0.001 |
| LDLC (mmol/L) | 2.51 ± 0.82 | 2.55 ± 0.81 | 2.54 ± 0.85 | 2.48 ± 0.81 | 2.45 ± 0.80 | 0.021 |
| Serum UA (μmol/L) | 286 ± 105 | 305 ± 104 | 285 ± 101 | 285 ± 102 | 270 ± 108 | <0.001 |
| HbA1c (%) | 8.29 ± 1.23 | 8.51 ± 1.32 | 8.36 ± 1.22 | 8.23 ± 1.18 | 8.08 ± 1.14 | <0.001 |
| QTc (ms) | 419 ± 32 | 432 ± 33 | 423 ± 29 | 414 ± 31 | 408 ± 31 | <0.001 |
| Prolonged QTc, n (%) | 684 (23.4) | 278 (37.9) | 186 (25.6) | 131 (17.9) | 89 (12.1) | <0.001 |
Normally distributed values in the table are given as the mean ± SD, non-normally distributed values are given as the median (25 and 75% interquartiles), and categorical variables are given as frequency (percentage)
ISI insulin sensitivity index of Matsuda, QTc heart rate-corrected QT, BMI body mass index, SBP/DBP systolic/diastolic blood pressure, TC total cholesterol, TG triglyceride, HDLC high density lipoprotein cholesterol, LDLC low density lipoprotein cholesterol, Serum UA serum uric acid, HbA1c glycosylated hemoglobin A1c, CHD coronary heart disease
p values for continuous variables and categorical variables were determined by ANOVA and the Chi squared test, respectively
Fig. 1The distribution of the QTc interval
Fig. 2The distribution of the ISIMatsuda
Fig. 3The relationship between the QTc interval and the ISIMatsuda
Fig. 4The proportion of prolonged QTc interval (>440 ms) stratified by ISIMatsuda quartiles (p for trend <0.001)
Multiple linear regression analysis to explore in dependent risks of QTc interval
| Variables | B | SE |
|
|
|
|
|---|---|---|---|---|---|---|
| log ISIMatsuda | −11.22 | 0.89 | −0.23 | −12.63 | <0.001 | 8.5 |
| Female | 16.11 | 1.21 | 0.22 | 12.27 | <0.001 | 6.1 |
| Age | 0.32 | 0.045 | 0.13 | 7.05 | <0.001 | 2.5 |
| Hypertension | 5.10 | 1.26 | 0.078 | 4.05 | <0.001 | 0.7 |
| Insulin treatments | 4.23 | 1.23 | 0.062 | 3.44 | 0.001 | 0.4 |
| Serum UA | 0.018 | 0.006 | 0.059 | 3.056 | 0.002 | 0.3 |
B regression coefficient, SE standard error, β standardized coefficient
ORs for prolonged QTc interval according to ISIMatsuda quartiles (95% CI)
| ISIMatsuda quartiles | Q1 | Q2 | Q3 | Q4 |
|
|---|---|---|---|---|---|
|
| 733 | 727 | 730 | 737 | – |
| Model 1 | 4.45 (3.41–5.81) | 2.50 (1.89–3.30) | 1.59 (1.19–2.13) | 1-Reference | <0.001 |
| Model 2 | 4.29 (3.25–5.65) | 2.46 (1.85–3.26) | 1.59 (1.18–2.14) | 1-Reference | <0.001 |
| Model 3 | 3.58 (2.62–4.88) | 2.12 (1.56–2.89) | 1.55 (1.13–2.14) | 1-Reference | <0.001 |
| Model 4 | 3.12 (2.24–4.34) | 2.08 (1.50–2.87) | 1.50 (1.07–2.11) | 1-Reference | <0.001 |
| Model 5 | 3.11 (2.23–4.34) | 2.09 (1.51–2.88) | 1.53 (1.09–2.14) | 1-Reference | <0.001 |
Model 1 unadjusted model, Model 2 adjusted for age and diabetic duration, Model 3 additionally adjusted for female, BMI, SBP, DBP, drinking, smoking, statins medication, hypertension and history of CHD, Model 4 additionally adjusted for HbA1c, serum UA, TG, TC, HDLC, and LDLC, Model 5 additionally adjusted for lifestyle intervention alone, insulin treatments, insulin secretagogues and insulin sensitizers